KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rigel Pharmaceuticals (RIGL) Current Deferred Revenue (2016 - 2025)

Historic Current Deferred Revenue for Rigel Pharmaceuticals (RIGL) over the last 15 years, with Q3 2025 value amounting to $1.4 million.

  • Rigel Pharmaceuticals' Current Deferred Revenue changed 0.0% to $1.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.4 million, marking a year-over-year change of 0.0%. This contributed to the annual value of $1.4 million for FY2024, which is 0.0% changed from last year.
  • According to the latest figures from Q3 2025, Rigel Pharmaceuticals' Current Deferred Revenue is $1.4 million, which was down 0.0% from $1.4 million recorded in Q2 2025.
  • Rigel Pharmaceuticals' 5-year Current Deferred Revenue high stood at $9.5 million for Q1 2021, and its period low was $1.4 million during Q2 2023.
  • Its 5-year average for Current Deferred Revenue is $2.2 million, with a median of $1.4 million in 2023.
  • Per our database at Business Quant, Rigel Pharmaceuticals' Current Deferred Revenue soared by 36273.75% in 2021 and then plummeted by 7792.63% in 2022.
  • Quarter analysis of 5 years shows Rigel Pharmaceuticals' Current Deferred Revenue stood at $2.6 million in 2021, then plummeted by 47.27% to $1.4 million in 2022, then fell by 1.02% to $1.4 million in 2023, then changed by 0.0% to $1.4 million in 2024, then changed by 0.0% to $1.4 million in 2025.
  • Its Current Deferred Revenue stands at $1.4 million for Q3 2025, versus $1.4 million for Q2 2025 and $1.4 million for Q1 2025.